CureMetrix is committed to the advancement of technology that will improve cancer survival rates worldwide. We are focused on developing the next generation of medical imaging technology that healthcare providers and patients can confidently rely on.
Using our patent-pending algorithm, we are developing an adjunct, precision tool for mammography. Our goal is to equip radiologists with the objective, data-driven answers they need to support patients and their healthcare team as they make decisions about their breast cancer screening, treatment and diagnosis. At CureMetrix, we believe that providing radiologists with the most advanced technology to support their evaluation of mammograms will lead to improved clinical outcomes, reduced healthcare costs and increased assurance that patients are getting the highest standard of imaging care available.
cmTriage™ from CureMetrix is our first FDA-cleared software that enables a radiologist to customize, sort, and prioritize their mammography worklist based on cases that may need immediate attention. Rather than today’s method of first in, first out for reading through a screening worklist, radiologists can now use cmTriage to identify which cases are suspicious and focus on those first.
Read more »
CureMetrix® entered the ring and wins a pilot contract with Philips. You can learn more about the process and outcome of the Philips event here.
Our investigational CureMetrix CAD software demonstrates its potential to:
Results from preliminary studies across thousands of images suggest that our algorithm can reduce false positive rates that may lead to unnecessary follow-up procedures and undue anxiety among patients.
We are developing powerful technology that could enable health care providers to hone in on even the most microscopic changes more quickly and accurately than ever before.
We are designing our image analysis platform to improve the evaluation of dense breasts using mammography.
Our algorithm has the potential to help physicians track the rate of change of growth of lesions over time, which may enable more informed follow-up and treatment decisions.
We seek to develop technology that will identify and classify the most suspicious anomalies and discard the likely benign ones, which may help radiologists improve their triage process and focus where it matters most.
The CureMetrix image analysis platform is the foundation that, when successful, will allow us to extend our technology across modality, anatomy and disease states.
